A Review of the Pharmaceutical Industry of Canada

Lalitha N ()

Working Papers from eSocialSciences

Abstract: Three important aspects of the Canadian pharmaceutical industry-viz. compulsory licence, price control on patented drugs and the R&D scenario. Unlike other developed countries, which have adopted the route of providing higher Intellectual Property Rights (IPR) protection to promote the growth of the domestic pharmaceutical industry, Canada chose to limit the IPRs on important pharmaceutical products. Though the pharmaceutical industry of India and Canada share a few common points of comparison, the most important point of divergence between Canada and India is that while the Indian pharmaceutical industry is supported by a well-established homegrown fine chemical industry, Canada lacks this advantage. [Working Paper No. 151].

Keywords: IPRs, divergence, India, chemical industry, Canada, Pharmaceutical industry, Compulsory, licensing, Research and development; patents, R&D, patented drugs, intellectual property rights, price control (search for similar items in EconPapers)
Date: 2008-01
Note: Institutional Papers
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://www.esocialsciences.org/Download/repecDownl ... &AId=1343&fref=repec

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ess:wpaper:id:1343

Access Statistics for this paper

More papers in Working Papers from eSocialSciences
Bibliographic data for series maintained by Padma Prakash ().